ARID1A and bladder transitional cell carcinoma: Subsequently, we applied the validated antibody to analyze a large cohort of urothelial bladder carcinomas (n = 362) and normal urothelial (NU) controls (n = 21) for ARID1A protein expression loss as a potential surrogate for ARID1A truncating mutations.